This systematic review and network meta-analysis found that spinal cord stimulation therapies for treatment of chronic pain in back and/or lower extremities were associated with greater improvements ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.

Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.

Inceptiv is a small device, implanted in the lower torso with leads to the spinal cord, that provides responsive counter-stimulation to relieve chronic pain. The device was approved by the FDA in ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

Philadelphia-based Rothman Orthopaedic Institute has been at the forefront of spine care, and recently a team partnered with Thomas Jefferson University Hospita ...

US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

Researchers at Kennedy Krieger Institute’s International Center for Spinal Cord Injury (ICSCI) have made a remarkable ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Australian researchers are about to launch a human trial to treat spinal cord injury by transplanting cells from the noses of paralysed patients into the damaged area. Griffith University ...